JPRN-jRCT2051230028招募中3 期
Regenerative Therapy for Soft Tissue Defects of the External Auditory Meatus with NPC-18
Kanemaru Shin-ichi0 个研究点目标入组 20 人开始时间: 2023年5月26日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 < 90age old（—）
- 性别
- All
入选标准
- •1)Subject has given written informed consent. For subject under 18 years of age, subject and their legal representatives (care givers, parents) have given written consent (or assent if under 16 years of age).
- •2)Subject aged between 12 and 90 years of age at the time of consent.
- •3)Subject has unilateral intractable Grade I soft tissue defect of external auditory meatus (EAM) due to trauma inflicted 3 months or more prior to study treatment initiation.
- •4)Subject has soft tissue defect of EAM which has not tended to heal at least 3 weeks or more from screening phase (Visit S1) to the start day of study treatment initiation (Visit T1), if unilateral Grade I soft tissue defect of EAM due to trauma occurred less than 3 months prior to study treatment initiation.
- •5)Subject has unilateral Grade II or III soft tissue defect of EAM due to trauma inflicted one month or more prior to study treatment initiation.
- •6)Subject has or is expected to have unilateral soft tissue defect of EAM due to surgical treatment.
排除标准
- •1)Subject has soft tissue defect of EAM due to burns or radiotherapy.*
- •2)Subject has external auditory canal cholesteatoma extending within the mastoid cells or within the tympanic cavity.*
- •3)Subject has malignancy/suspected malignancy or a history of malignancy in the ear.*
- •4)Subject has otitis externa or active otitis media.*
- •5)Subject has infection or otorrhea of tympanic membrane, EAM, middle ear or tympanic cavity detected by inspection through a microscope.*
- •6)Subject has a history of external or middle ear surgery.*
- •7)Subject has uncontrolled diabetes mellitus (HbA1c levels of 8.0 percent or more).
- •8)Subject has autoimmune diseases.
- •9)Subject has a history of malignancy or malignancy within 3 years prior to the time of consent.
- •10)Subject has received any immunosuppressants.
- •11)Subject has received any form of corticosteroids such as oral medications, ear drops or injections.
- •12)Subject has received any form of anticoagulants (warfarin, direct-acting oral anticoagulants, heparin, etc.), thrombolytics or antiplatelet agents (aspirin, clopidogrel, etc.) and cannot be withdrawn for medical reasons before or after ear canal revision.
- •13)Subject has received any coagulant (snake venom preparation) or antifibrinolytic.
- •14)Prothrombin time-international standard ratio (PT-INR)>1.5xULM.
- •15)Activated partial thromboplastin time (APTT) >1.5xULM.
- •16)Subject has a history of hypersensitivity to any of lidocaine or fibroblast growth factor (b-FGF).
- •17)Subject has a history of hypersensitivity to any of gelatin sponge or gelatin.
- •18)Subject has a history of hypersensitivity to antibiotics.
- •19)Female subject is pregnant or breastfeeding, or male subject is expecting to conceive or father children during the study period/Subject is unable to use any adequate contraception such as condoms, pills, pessaries, IUDs, implantable devices, spermicides, etc. during the study period.
- •20)Subject has a known history of a positive test for hepatitis B virus (HBsAg), hepatitis C virus (HCVAb), human immunodeficiency virus (HIVAg or Ab) or syphilis serology.
- •21)Subject has a history of alcohol or drug abuse.
- •22)Subject has any significant disease including hepatic, renal, cardiovascular, respiratory, hematological or metabolic disease.
- •23)Subject has any neuropsychiatric disease.
- •24)Subject has participated in any other clinical trial or has received any other study drug within 3 months prior to consent.
- •25)Subject has bilateral soft tissue defects of EAM due to trauma occurred.
- •26)Otherwise, subject is determined to be ineligible for this study by the investigator or sub-investigator.
- •*The ear conducting the protocol treatment
研究者
相似试验
已完成
不适用
The study of tissue regeneration and promotion of heeling for meniscal tear and regenerative meniscus.meniscal tear degenerative meniscusJPRN-UMIN000022600Aichi Medical University60
尚未招募
不适用
Is platelet-rich plasma (a blood product) helpful in treating lichen sclerosus on the vulva (external female genitalia)?vulvar lichen sclerosusACTRN12618001321235Dr Fariba Behnia Willison68
招募中
2 期
ovel Regenerative Therapy with Autologus Myoblast Sheet for Pediatric Heart Failure patientsSevere Cardiomyopathy in Pediatric patietnsJPRN-UMIN000013941Department of Cardiovascular Surgery, Graduate School of medicine, Osaka University15
终止
不适用
on-healing soft tissue and malignant wounds in the palliative care setting: applying Sterile Larvae Wound Therapy for wound debridement and healing.malignant woundsnon-healing soft tissueSkin - Other skin conditionsCancer - Any cancerACTRN12619000920190St Vincent's Private Hospital Brisbane1
已完成
不适用
Development of a new tissue regeneration technology using human adipose-derived stem cellJPRN-jRCT1090220126Junko Nakahira30